← Analysis
We could not get people to notice RNA
Katalin Kariko started working on messenger RNA at the University of Pennsylvania in 1989, trying to solve a problem nobody was funding: synthetic mRNA triggered a violent immune reaction that made it useless as a therapy. Grant applications were rejected. She was demoted four times, once while being treated for cancer, and chose the demotion and a pay cut over abandoning the research. In 2005, she and immunologist Drew Weissman found the fix, a modified nucleoside that let synthetic mRNA slip past the body's defenses, and submitted it to Nature and Science. Both rejected it as not novel and not of interest to a broad readership. It ran in the journal Immunity instead. Fifteen years later, that fix was the reason a coronavirus vaccine could be built and authorized in under a year instead of the usual decade or more. Kariko and Weissman won the Nobel Prize in 2023.

Katalin Kariko began working on messenger RNA at the University of Pennsylvania in 1989, pursuing an idea most of the field considered a dead end: using synthetic mRNA to instruct the body's own cells to produce a needed protein, rather than delivering the protein or a virus directly. The obstacle was immediate and severe — injected synthetic mRNA triggered a violent immune response, inflammation serious enough to make the approach look unworkable, and grant reviewers funded accordingly.[1]

Kariko's funding never arrived at any scale that let the work continue on ordinary terms. She was demoted four times during her years at Penn, moved from lab to lab as a research assistant professor with no permanent position in sight. In the late 1990s, while being treated for cancer, the university gave her a choice: leave, or accept another demotion and a pay cut. She chose the demotion, and kept working on mRNA.[2]

In 2005, Kariko and immunologist Drew Weissman found the specific fix: substituting a modified nucleoside into the synthetic mRNA let it slip past the immune system's defenses without triggering the inflammatory response that had blocked the whole approach for sixteen years. They submitted the finding to Nature and to Science. Both rejected it — reviewers called the work "not novel" and "not of interest to the broad readership." It was eventually published in the journal Immunity, well outside the field's most-read venues.[3] Weissman's own account of the years that followed: "we could not get funding or publication — we could not get people to notice RNA."[3]

Nobody funding, publishing, or rejecting that work in 1989 or in 2005 knew what it would eventually be needed for. A novel coronavirus emerging from Wuhan in late 2019 was not a contingency anyone's grant committee was underwriting research against. Ordinary vaccine development takes ten to fifteen years from a standing start; the fastest vaccine ever developed before this one, for mumps in 1967, took four.[4] The nucleoside-modification fix, sixteen years old and still barely funded when the pandemic began, meant the biological hard part — how to make synthetic mRNA the body would actually accept — did not have to be solved from scratch. The FDA issued an emergency use authorization for the Pfizer-BioNTech vaccine on December 11, 2020, and for Moderna's a week later, both built on that same fix.[5]

Kariko left academic research for industry in 2013, joining BioNTech specifically because it offered a path to keep working on mRNA that a tenured research career had not.[6] In October 2023, she and Weissman were awarded the Nobel Prize in Physiology or Medicine.[6] The university that demoted her four times faced public calls to apologize once the prize was announced.[2]

This is not a story about one underappreciated scientist getting her due. It is the mechanism this site has already named run at the scale of a civilization's own immune system against new ideas: a tool built for reasons that had nothing to do with the specific crisis that would eventually need it, kept alive against the exact institutions — grant committees, peer reviewers, tenure panels — whose job was supposedly to recognize its value, and ready only because the people holding it refused every offramp for sixteen years before anyone else understood what it was for.

The takeaway Katalin Kariko began mRNA research at the University of Pennsylvania in 1989, working against a problem — synthetic mRNA triggering a dangerous immune reaction — that most of the field treated as a dead end. She was demoted four times over the following years, once while being treated for cancer, and chose demotion over abandoning the work. In 2005, she and Drew Weissman found the fix: a modified nucleoside letting synthetic mRNA evade the immune response. Nature and Science both rejected the finding as unremarkable; it ran in the journal Immunity instead. Fifteen years later, that same fix was the reason COVID-19 vaccines could be authorized in under a year, when ordinary vaccine development takes ten to fifteen. Kariko and Weissman won the 2023 Nobel Prize in Physiology or Medicine. Nobody funding or rejecting the work in 1989 or 2005 knew what it would be needed for. The tool was ready because the people holding it refused to let it go before anyone else understood what it was for.
Sources
  1. Scientific American, Katalin Karikó's Nobel Prize-Winning Work on mRNA Was Long Ignored-And Led to COVID Vaccines
  2. Forbes, Researcher Demoted By University Of Pennsylvania Wins Nobel Prize For mRNA Discoveries
  3. National Institutes of Health / PMC, From rejection to the Nobel Prize: Karikó and Weissman's pioneering work on mRNA vaccines
  4. Charles River, What History Tells Us About Vaccine Timetables
  5. CNN, FDA issues emergency use authorization for Pfizer/BioNTech Covid-19 vaccine
  6. Britannica, Katalin Kariko